Xilio Therapeutics Expands Board with New Director

Xilio Therapeutics ( (XLO) ) has provided an announcement.

On June 10, 2025, Xilio Therapeutics expanded its Board of Directors to ten members by electing Akintunde Bello, Ph.D., as a Class II director, with his term expiring at the 2026 annual meeting. Dr. Bello’s appointment to the Nominating and Corporate Governance Committee is expected to enhance the company’s governance and strategic direction.

The most recent analyst rating on (XLO) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Xilio Therapeutics stock, see the XLO Stock Forecast page.

Spark’s Take on XLO Stock

According to Spark, TipRanks’ AI Analyst, XLO is a Neutral.

Xilio Therapeutics receives a moderate score due to a mix of promising strategic partnerships and ongoing financial challenges. The partnership with AbbVie is a notable positive, providing potential financial and strategic benefits. However, the company’s current lack of profitability and negative cash flow impact the overall evaluation. Technical analysis indicates short-term momentum, but longer-term trends remain a concern. The valuation reflects the company’s current unprofitability.

To see Spark’s full report on XLO stock, click here.

More about Xilio Therapeutics

Xilio Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for cancer treatment.

Average Trading Volume: 1,257,834

Technical Sentiment Signal: Sell

Current Market Cap: $36.25M

For detailed information about XLO stock, go to TipRanks’ Stock Analysis page.